Edition:
United States

GlaxoSmithKline PLC (GSK.N)

GSK.N on New York Stock Exchange

40.56USD
28 Jul 2017
Change (% chg)

$-0.19 (-0.48%)
Prev Close
$40.75
Open
$40.35
Day's High
$40.65
Day's Low
$40.28
Volume
288,423
Avg. Vol
693,638
52-wk High
$45.58
52-wk Low
$37.20

Latest Key Developments (Source: Significant Developments)

GSK non-core tail brands could sell for 0.5-1.0 bln pounds
Wednesday, 26 Jul 2017 10:45am EDT 

July 26 (Reuters) - GlaxoSmithKline CFO Simon Dingemans tells analysts::c.130 non-core tail brands with annual sales of 0.5 billion stg could sell for 1-2x sales.  Full Article

GSK CEO comments on Q2 results, business priorities
Wednesday, 26 Jul 2017 07:31am EDT 

July 26 (Reuters) - GlaxoSmithKline CEO Emma Walmsley told reporters::Ceo says absolutely committed to three-business structure of group.Ceo says business model provides stability of cash flows.Ceo says says will make progressive withdrawal from tanzeum diabetes business in u.s..Ceo says one m&a area where will be quite focused is early-stage pharma deals to bolster pipeline.Ceo says should not expect research and development budget to come down as result of pipeline review.Ceo says research and development spend per drug asset has been too low in the past.Ceo says does not want to put a number on future potential job losses.Ceo says encouraged by more pragmatic approach from uk government on brexit following recent letter from ministers.Ceo says.Ceo says wants long brexit transition and as much mutual drug recognition as possible.Ceo says absolute minimum brexit transition period needs to be 2 years, would like it to be longer.Ceo says partnership could be an option for oncology research and development assets.Ceo says would be 'delighted' to take on rest of consumer business but sale of stake up to novartis.Ceo says consolidation of u.s. Payers means pressure on drug prices will continue.  Full Article

ViiV announces positive results from DAWNING
Tuesday, 25 Jul 2017 08:30am EDT 

July 25 (Reuters) - Glaxosmithkline Plc ::VIIV ANNOUNCES POSITIVE RESULTS FROM DAWNING.VIIV HEALTHCARE, MAJORITY OWNED BY GSK, WITH PFIZER AND SHIONOGI AS SHAREHOLDERS, ANNOUNCED POSITIVE INTERIM RESULTS FROM DAWNING.  Full Article

GlaxoSmithKline says ViiV announces results from NEAT 022 study
Tuesday, 25 Jul 2017 08:30am EDT 

July 25 (Reuters) - Glaxosmithkline Plc :VIIV HEALTHCARE AND NEAT-ID ANNOUNCED RESULTS FROM NEAT 022 STUDY OF MORE THAN 400 PATIENTS WITH HIV AND HIGH CARDIOVASCULAR RISK.  Full Article

GSK says submits U.S. regulatory filing for asthma drug
Monday, 24 Jul 2017 08:20am EDT 

July 24 (Reuters) - Glaxosmithkline Plc ::GSK SUBMITS US REGULATORY FILING OF ARNUITY ELLIPTA IN CHILDREN WITH ASTHMA.FILING OF SNDA TO FDA FOR USE OF ARNUITY ELLIPTA AS MAINTENANCE TREATMENT OF ASTHMA AS PROPHYLACTIC THERAPY IN CHILDREN AGED 5-11 YRS.  Full Article

Glaxosmithkline receives FDA approval for new self-injectable formulation of Benlysta
Friday, 21 Jul 2017 09:00am EDT 

July 21 (Reuters) - Glaxosmithkline Plc ::Receives FDA approval for a new self-injectable formulation of benlysta (belimumab) for systemic lupus erythematosus.Benlysta subcutaneous formulation will be available in specialty pharmacies in us in late August.Further regulatory submissions for subcutaneous formulation of benlysta under review, planned in other countries during course of 2017.  Full Article

GSK and Innoviva submit EU filing for extended use of Relvar Ellipta
Friday, 21 Jul 2017 09:00am EDT 

July 21 (Reuters) - GlaxoSmithKline plc ::GSK submits EU filing for extended use of Relvar Ellipta in patients with controlled asthma on an ICS/LABA combination.  Full Article

Glaxosmithkline submits EU filing for Relvar Ellipta extension
Friday, 21 Jul 2017 08:51am EDT 

July 21 (Reuters) - Glaxosmithkline Plc ::Submits EU filing for extended use of Relvar Ellipta in patients with controlled asthma on an ICS/LABA combination.  Full Article

GSK to sell UK Horlicks business
Wednesday, 19 Jul 2017 07:30am EDT 

July 19 (Reuters) - Glaxosmithkline Plc ::Announces updates on UK manufacturing network.Proposals announced today for Worthing and Slough will result in a reduction of approximately 320 permanent jobs over next 4 years.Between now and 2020, plans to invest more than 140 mln stg at Ware, Hertfordshire, Barnard Castle, Co Durham, Montrose, Scotland sites.Investments will support expansion of manufacturing for respiratory and HIV medicines.In its consumer healthcare business, company intends to sell its Horlicks brand in UK.GSK is also exploring options to divest some other smaller non-core nutrition brands.Proposing to close associated manufacturing site in slough where UK product is made.None of announcements made today by company have resulted from UK's decision to leave European Union.In pharmaceuticals, co to undertake a strategic review of Cephalosporins antibiotics business.Company has also decided not to proceed with previously planned investment to build biopharmaceutical facility in Ulverston.  Full Article

GSK considering selling off its Horlicks business- BBC
Wednesday, 19 Jul 2017 05:58am EDT 

July 19 (Reuters) - :GSK is considering selling off its Horlicks business- BBC.  Full Article

Photo

GlaxoSmithKline's new boss streamlines R&D, axes slew of drugs

LONDON GlaxoSmithKline's new chief executive announced plans on Wednesday to narrow the focus of the group's drug research by ditching more than 30 drug projects to improve returns in its core pharmaceuticals business.